Markus Werner

Markus Werner

Auto-generated profile, based on publicly available information

Markus Werner

Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, 07743 Jena, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Science Signaling
Verified
Journal Article
Closed access
NSNils Helge Schebb
Nils Helge Schebb
NKNadja Kampschulte
Nadja Kampschulte
Gerhard HagnGerhard Hagn
Gerhard Hagn
KPKathrin Plitzko
Kathrin Plitzko
SMSven W. Meckelmann
Sven W. Meckelmann
VOValerie B. O’Donnell
Valerie B. O’Donnell
Several oxylipins are potent lipid mediators that regulate diverse aspects of health and disease and whose quantitative analysis by liquid chromatography–mass spectrometry (LC-MS) presents substantial technical challenges. As members of the lipidomics community, we developed technical recommendations to ensure best practices when quantifying oxylipins by LC-MS.

4 December 2018 in Marine Drugs
Verified
Journal Article
Open access
PDF file
NMNils Meyer
Nils Meyer
JRJohanna Rettner
Johanna Rettner
MWMarkus Werner
Markus Werner
OWOliver Werz
Oliver Werz
GPGeorg Pohnert
Georg Pohnert
Algicidal bacteria can lyse microalgal blooms and trigger shifts within plankton communities. Resistant algal species can escape lysis, and have the opportunity to dominate the phytoplankton after a bacterial infection. Despite their important function in ecosystem regulation, little is known about mechanisms of resistance. Here, we show that the diatom Chaetoceros didymus releases eicosanoid oxylipins into the medium, and that the lytic algicidal bacterium, Kordia algicida, induces the production of several wound-activated oxylipins in this resistant diatom. Neither releases nor an induction occurs in the susceptible diatom Skeletonema costatum that is lysed by the bacterium within a few days. Among the upregulated oxylipins, hydroxylated eicosapentaenoic acids (HEPEs) dominate. However, also, resolvins, known lipid mediators in mammals, increase upon exposure of the algae to the algicidal bacteria. The prevailing hydroxylated fatty acid, 15-HEPE, significantly inhibits growth of K. algicida at a concentration of approximately 1 µM. The oxylipin production may represent an independent line of defense of the resistant alga, acting in addition to the previously reported upregulation of proteases.

21 August 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ZRZhigang Rao
Zhigang Rao
EBElena Brunner
Elena Brunner
BGBenjamin Giszas
Benjamin Giszas
AIAishwarya Iyer-Bierhoff
Aishwarya Iyer-Bierhoff
JGJana Gerstmeier
Jana Gerstmeier
OWOliver Werz
Oliver Werz
Glucocorticoids (GC) are potent anti-inflammatory agents, broadly used to treat acute and chronic inflammatory diseases, e.g., critically ill COVID-19 patients or patients with chronic inflammatory bowel diseases. GC not only limit inflammation but also promote its resolution although the underlying mechanisms are obscure. Here, we reveal reciprocal regulation of 15-lipoxygenase (LOX) isoform expression in human monocyte/macrophage lineages by GC with respective consequences for the biosynthesis of specialized proresolving mediators (SPM) and their 15-LOX-derived monohydroxylated precursors (mono-15-OH). Dexamethasone robustly up-regulated pre-mRNA, mRNA, and protein levels of ALOX15B/15-LOX-2 in blood monocyte–derived macrophage (MDM) phenotypes, causing elevated SPM and mono-15-OH production in inflammatory cell types. In sharp contrast, dexamethasone blocked ALOX15/15-LOX-1 expression and impaired SPM formation in proresolving M2-MDM. These dexamethasone actions were mimicked by prednisolone and hydrocortisone but not by progesterone, and they were counteracted by the GC receptor (GR) antagonist RU486. Chromatin immunoprecipitation (ChIP) assays revealed robust GR recruitment to a putative enhancer region within intron 3 of the ALOX15B gene but not to the transcription start site. Knockdown of 15-LOX-2 in M1-MDM abolished GC-induced SPM formation and mono-15-OH production. Finally, ALOX15B/15-LOX-2 upregulation was evident in human monocytes from patients with GC-treated COVID-19 or patients with IBD. Our findings may explain the proresolving GC actions and offer opportunities for optimizing GC pharmacotherapy and proresolving mediator production.

14 August 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
YDYun Deng
Yun Deng
RYRuyi Yu
Ruyi Yu
VGVeit Grabe
Veit Grabe
TSThomas Sommermann
Thomas Sommermann
MWMarkus Werner
Markus Werner
GPGeorg Pohnert
Georg Pohnert
The bloom and bust patterns of microalgae in aquatic systems contribute massively to global biogeochemical cycles. The decline of algal blooms is mainly caused by nutrient limitation resulting in cell death, the arrest of cell division and the aging of surviving cells. Nutrient intake can re-initiate proliferation, but the processes involved are poorly understood. Here we characterize how the bloom-forming diatom Coscinodiscus radiatus recovers from starvation after nutrient influx. Rejuvenation is mediated by extracellular vesicles that shuttle reactive oxygen species, oxylipins and other harmful metabolites out of the old cells, thereby re-enabling their proliferation. By administering nutrient pulses to aged cells and metabolomic monitoring of the response, we show that regulated pathways are centred around the methionine cycle in C. radiatus. Co-incubation experiments show that bacteria mediate aging processes and trigger vesicle production using chemical signalling. This work opens new perspectives on cellular aging and rejuvenation in complex microbial communities.

10 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FBFriedemann Börner
Friedemann Börner
MWMarkus Werner
Markus Werner
JEJohannes Ertelt
Johannes Ertelt
JMJürgen Meins
Jürgen Meins
MTMona Abdel Tawab
Mona Abdel Tawab
OWOliver Werz
Oliver Werz
Extracts of frankincense, the gum resin of Boswellia species, have been extensively used in traditional folk medicine since ancient times and are still of great interest as promising anti-inflammatory remedies in Western countries. Despite their common therapeutic use and the intensive pharmacological research including studies on active ingredients, modes of action, bioavailability, pharmacokinetics, and clinical efficacy, frankincense preparations are available as nutraceuticals but have not yet approved as a drug on the market. A major issue of commercially available frankincense nutraceuticals is the striking differences in their composition and quality, especially related to the content of boswellic acids (BAs) as active ingredients, mainly due to the use of material from divergent Boswellia species but also because of different work-up and extraction procedures. Here, we assessed three frequently used frankincense-based preparations for their BA content and the interference with prominent pro-inflammatory actions and targets that have been proposed, that is, 5-lipoxygenase and leukotriene formation in human neutrophils, microsomal prostaglandin E2 synthase-1, and inflammatory cytokine secretion in human blood monocytes. Our data reveal striking differences in the pharmacological efficiencies of these preparations in inflammation-related bioassays which obviously correlate with the amounts of BAs they contain. In summary, high-quality frankincense extracts display powerful anti-inflammatory effectiveness against multiple targets which can be traced back to BAs as bioactive ingredients.

1 April 2016 in Pharmacological Research
Verified
Journal Article
Closed access
Antonietta RossiAntonietta Rossi
Antonietta Rossi
SPSimona Pace
Simona Pace
FTFederica Tedesco
Federica Tedesco
Ester PaganoEster Pagano
Ester Pagano
Germano GuerraGermano Guerra
Germano Guerra
Raffaele CapassoRaffaele Capasso
Raffaele Capasso